Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction

American Heart Journal

Volumn 144, Issue 6, 2002, Pages 1003-1011

  Walsh, Craig R ^a,c   O'Donnell, Christopher J ^a,c,d   Camargo Jr , Carlos A ^a,b   Giugliano, Robert P ^a,b   Lloyd Jones, Donald M ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

^d Premium Heart Study   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0036910778     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.125504     Document Type: Article

References (38)

1. US Renal Data System. USRDS 1998 Annual Data Report. Bethesda, Md: National Institutes of Health and National Institute of Diabetes, Digestive, Kidney Disease; 1998.
2. Herzog CA, Ma JZ, Collins AJ. Long-term survival of renal transplant recipients in the United States after acute myocardial infarction. Am J Kidney Dis 2000;36:145-52.
3. Herzog CA, MA JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. New Engl J Med 1998;339:799-805.
4. Sadaniantz A, Wu WC. Survival of renal transplant patients after first myocardial infarction: A look to the past and promises for the future. Am J Kidney Dis 2000;36:211-3.
5. Chertow GM, Normand SL, Silva LR, et al. Survival after acute myocardial infarction in patients with end-stage renal disease: Results from the cooperative cardiovascular project. Am J Kidney Dis 2000;35:1044-51.
6. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-9.
7. Marso SP, Ellis SG, Gurm HS, et al. Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. Am Heart J 2000;139:939-44.
8. Marso SP, Ellis SG, Tuzcu M, et al. The importance of proteinuria as a determinant of mortality following percutaneouscoronary revascularization in diabetics. J Am Coll Cardiol 1999;33:1269-77.
9. Becker BN, Himmelfarb J, Henrich WL, et al. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997;8:475-86.
10. Venkatesan J, Henrich WL. Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Semin Nephrol 1997;17:257-69.
11. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999;10:891-900.
12. Jacobs DRJ, Kroenke C, Crow R, et al. PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: The Minnesota heart survey. Circulation 1999;100:599-607.
13. Matts JP, Karnegis JN, Campos CT, et al. Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. J Fam Pract 1993;36:497-503.
14. McCullough PA, Soman SS, Shah SS, et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000;36:679-84.
15. Normand ST, Glickman ME, Sharma RG, et al. Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients: Results from the Cooperative Cardiovascular Project. JAMA 1996;275:1322-8.
16. Schlant RC, Forman S, Stamler J, et al. The natural history of coronary heart disease: Prognostic factors after recovery from myocardial infarction in 2789 men: The 5-year findings of the coronary drug project. Circulation 1982;66:401-14.
17. Van Ruiswyk J, Hartz A, Kuhn E, et al. A measure of mortality risk for elderly patients with acute myocardial infarction. Med Decis Making 1993;13:152-60.
18. Lloyd-Jones DM, Camargo CA Jr, Giugliano RP, et al. Characteristics and prognosis of patients with suspected acute myocardial infarction and elevated MB relative index but normal total creatine kinase. Am J Cardiol 1999;84:957-62.
19. Bowers LD, Wong ET. Kinetic serum creatinine assays II: A critical evaluation and review. Clin Chem 1980;26:555-61.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
22. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992;268:1417-22.
23. Iezzoni LI, Burnside S, Sickles L, et al. Coding of acute myocardial infarction: Clinical and policy implications. Ann Intern Med 1988;109:745-51.
24. Kennedy GT, Stern MP, Crawford MH. Miscoding of hospital discharges as acute myocardial infarction: Implications for surveillance programs aimed at elucidating trends in coronary artery disease. Am J Cardiol 1984;53:1000-2.
25. Foley RN, Parfrey PS, Kent GM, et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000;11:912-6.
26. Foley RN, Parfrey PS, Kent GM, et al. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998;54:1720-5.
27. Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease: Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979;59:421-30.
28. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
29. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998;316:1337-43.
30. The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post infarction patients. The Beto-Blocker Pooling Project Research Group. Eur Heart J 1988;9:8-16.
31. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992; 327:669-77.
32. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001;134:629-36.
33. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. FRISC II investigators. Fast revascularisation during instability in coronary artery disease. Lancet 2000;356:9-16.
34. Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998;128:194-203.
35. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80:11-20B.
36. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489-510S.
37. Lefevre G, Duval M, Gauron S, et al. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther 1997;62:50-9.
38. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: New insights into old concepts. Clin Chem 1992;38:1933-53.